成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>217645-70-0

217645-70-0

中文名稱 (R)-1-(5-氯-2-(2-(4-(4-氟芐基)-2-甲基哌嗪-1-基)-2-氧代乙氧基)苯基)脲
英文名稱 Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)Methyl]-2-Methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-
CAS 217645-70-0
分子式 C21H24ClFN4O3
分子量 434.892
MOL 文件 217645-70-0.mol
更新日期 2024/10/21 13:57:00
217645-70-0 結構式 217645-70-0 結構式

基本信息

中文別名
化合物BX-471
(2R)-1-[[[4-氯-2-(脲基)苯氧基]甲基]羰基]-2-甲基-4-(4-氟芐基)哌嗪
(R)-1-[5-氯-2-[2-[4-(4-氟芐基)-2-甲基哌嗪-1-基]-2-氧代乙氧基]苯基]脲
英文別名
CS-1299
BX471(ZK-811752)
ZK811752 (BX471)
BX-471(Free base)
ZK-811752(BX-471) (free base)
BX471 - CAS 217645-70-0 - Calbiochem
ZK 811752
ZK811752
ZK-811752
BX-471
BX 471
BX-471
(5-Chloro-2-{2-[4-(4-fluoro-benzyl)-2-Methyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-urea
(R)-1-[5-Chloro-2-[2-[4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea
(2R)-1-[[[4-Chloro-2-(ureido)phenoxy]methyl]carbonyl]-2-methyl-4-(4-fluorobenzyl)piperazine
所屬類別
生物化工:激動劑抑制劑

物理化學性質

沸點593.5±50.0 °C(Predicted)
密度1.346±0.06 g/cm3(Predicted)
儲存條件2-8°C
儲存條件Inert atmosphere,2-8°C
溶解度二甲基亞砜:≥25mg/mL
酸度系數(shù)(pKa)13.66±0.70(Predicted)
形態(tài)白色粉末
顏色白色至棕褐色

安全數(shù)據(jù)

危險性符號(GHS)GHS hazard pictograms
GHS07
警示詞警告
危險品標志Xn,N
危險類別碼22-50
安全說明61
WGK Germany3
海關編碼2933.59.8000
(R)-1-(5-氯-2-(2-(4-(4-氟芐基)-2-甲基哌嗪-1-基)-2-氧代乙氧基)苯基)脲價格(試劑級)
報價日期產(chǎn)品編號產(chǎn)品名稱CAS號包裝價格
2024/08/19B6060BX 471
BX 471
217645-70-05mg295元
2024/08/19B6060BX 471
BX 471
217645-70-025mg1080元

常見問題列表

生物活性
BX471 (ZK-811752) 是以一種口服有效的,選擇性,非多肽的 CCR1 拮抗劑,Ki 值為 1 nM,對其選擇性是對 CCR2,CCR5 和 CXCR4 的 250 倍。
靶點

MIP-1α-CCR1

1 nM (Ki)

RANTES-CCR1

2.8 nM (Ki)

MCP-3-CCR1

5.5 nM (Ki)

體外研究

BX471 is a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca 2+ mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration. BX471 demonstrats a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors. BX471 is also able to displace 125 I-MIP-1α/CCL3 binding to mouse CCR1 in a concentration-dependent manner with a K i of 215±46 nM. Increasing concentrations of BX471 inhibits the Ca 2+ transients induced by MIP-1α/CCL3 in both human and mouse CCR1 with IC 50 of 5.8±1 nM and 198±7 nM, respectively. BX471 (0.1-10 μM) shows a dose-dependent inhibition of RANTES-mediated and shear-resistant adhesion on IL-1β-activated microvascular endothelium in shear flow in isolated blood monocytes. BX471 also inhibits the RANTES-mediated adhesion of T lymphocytes to activated endothelium.

體內(nèi)研究

BX471 (4 mg/kg, p.o. or i.v.) is orally active with a bioavailability of 60% in dogs. Furthermore, BX471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis. BX471 (20 mg/kg, s.c.) reaches peak plasma levels of 9 μM by around 30 minutes, and this rapidly declines to approximately 0.4 μM after 2 hours. From 4 to 8 hours the drug plasma levels drops to 0.1 μM or lower. Mice treated with 20 mg/kg of BX471 for 10 days shows a reduction of interstitial CD45 positive leukocytes of approximately 55%. BX471 has a borderline significant effect on the number of CCR5-positive CD8 cells in the peripheral blood. BX471 reduces the amount of FSP1-positive cells by 65% in UUO kidneys as compared with vehicle control. Pretreatment witih BX471 reduces macrophage and neutrophil accumulation in kidney after ischemia-reperfusion injury.

"217645-70-0" 相關產(chǎn)品信息
208260-29-1 139180-30-6 690206-97-4